Correction to: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial (Nature Medicine, (2024), 30, 9, (2517-2527), 10.1038/s41591-024-03076-6)

Steven M. Horwitz, Ajit J. Nirmal, Jahan Rahman, Ran Xu, Esther Drill, Natasha Galasso, Nivetha Ganesan, Theresa Davey, Helen Hancock, Leslie Perez, Catherine Maccaro, Alexandra Bahgat, Evan Marzouk, Elizabeth Cathcart, Alison Moskowitz, Ariela Noy, Anita Kumar, Eric Jacobsen, David C. Fisher, Neha Mehta-ShahYoun H. Kim, Michael Khodadoust, Nikita Kotlov, Anastasia Nikitina, Olga Kudryashova, Valeria Zubareva, Ksenia Zornikova, Nara Shin, Maria Sorokina, Sandrine Degryse, Ekaterina Postovalova, Aleksander Bagaev, Kinga Hosszu, Devin McAvoy, Jaap J. Boelens, Wenchao Wu, Zoe Ciantra, Jackson W. Appelt, Christopher Trevisani, Sam Amaka, David M. Weinstock, Santosha A. Vardhana

Research output: Contribution to journalComment/debate

Fingerprint

Dive into the research topics of 'Correction to: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial (Nature Medicine, (2024), 30, 9, (2517-2527), 10.1038/s41591-024-03076-6)'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science